Gyeonggi-do, South Korea

Ha Na Hwang

This inventor holds 1 USPTO granted patent. Top assignee: Daewoong Pharmaceutical Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ha Na Hwang. Retrieved from https://idiyas.com/inventor/ha-na-hwang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ha Na Hwang: Inventor in Pharmaceutical Packaging

Introduction

Ha Na Hwang is an inventor based in Gyeonggi-do, South Korea. His listed patent is associated with Daewoong Pharmaceutical Co., Ltd. and concerns a medicine container for a liquid pharmaceutical composition.

Latest Patents

Hwang is associated with 1 patent: “Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine.” The disclosure describes a medicine container holding a liquid pharmaceutical composition of the named compound or a pharmaceutically acceptable salt thereof.

Career Highlights

The available information connects Hwang’s patent work with Daewoong Pharmaceutical Co., Ltd. His listed invention focuses on containing a specific liquid pharmaceutical composition.

Collaborations

Gwan Young Kim and Yeon Jin Jung are identified as Hwang’s coworkers. The provided information does not specify their roles in the patent.

Conclusion

Ha Na Hwang’s listed patent reflects work on a medicine container designed for a particular liquid pharmaceutical composition, in association with Daewoong Pharmaceutical Co., Ltd.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…